Moreover, in a single-center phase II clinical trial on lung cancers harboring the KRAS G12C mutation, a complete response was seen in 3.2% of patients, and a partial response in 33.9% of patients, with a median duration of response of 11.1 months [13]. This evidence concerns the gene KRAS and lung cancer.